Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379340505> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W4379340505 endingPage "6540" @default.
- W4379340505 startingPage "6540" @default.
- W4379340505 abstract "6540 Background: Multiple novel therapies have recently been approved to treat acute myeloid leukemia (AML). Inequities in the uptake of novel treatments have been seen in other cancers but are not known for this population. Methods: We performed a retrospective analysis of the nationwide Flatiron Health electronic health record (EHR)-derived deidentified database. We assessed sociodemographic associations with novel AML therapies use within two-years of Food and Drug Administration (FDA) approval from 1/2014-8/2022. Therapies were: glasdegib, venetoclax, ivosidenib, midostaurin, CPX-351, gilteritinib, enasidenib, and gemtuzumab ozogamicin (GO). Univariable associations were assessed using X 2 testing. Logistic regression modeling of community practices assessed associations between novel therapy receipt and sociodemographics adjusted by treatment year. Variable categories are shown. Results: Of 8081 patients in 280 clinics, 3102 (38%) received at least one novel therapy. The cohort was predominately older (69; interquartile range [57, 77]), male (56%), non-Hispanic (NH)-White (88%), and treated at a community practice (75%). There were 4808 patients treated within 24-months of a novel therapy approval, of which 1937 (40%) received a novel therapy. Venetoclax represented 59% of novel treatments prescribed. Bivariate associations were seen between novel therapy receipt within 24-months of approval and high SES and non-Hispanic (NH)-White race-ethnicity; similar associations were seen when assessed at the treatment regimen level. In a logistic regression model of community practices (N=2,459), older patients (OR 1.01; 95%CI 1.00, 1.02), females (OR 1.2; 95% CI 1.0,1.4), and those from high (vs low) SES (OR 1.4; 95%CI 1.1, 1.6) were more likely to receive novel therapy; there were no associations with sex or race-ethnicity. Conclusions: In this large national database of adults with AML, almost half received novel therapy within 24-months of FDA approval. Though there was no dichotomous difference in uptake by race-ethnicity in community practices, younger and more affluent patients were more likely to receive novel therapy, concerning for disparities in uptake. [Table: see text]" @default.
- W4379340505 created "2023-06-05" @default.
- W4379340505 creator A5053981238 @default.
- W4379340505 creator A5066580309 @default.
- W4379340505 creator A5069251789 @default.
- W4379340505 creator A5077058201 @default.
- W4379340505 creator A5079159752 @default.
- W4379340505 creator A5082924494 @default.
- W4379340505 creator A5091710463 @default.
- W4379340505 creator A5031081188 @default.
- W4379340505 date "2023-06-01" @default.
- W4379340505 modified "2023-09-23" @default.
- W4379340505 title "Disparities in uptake of novel therapies for acute myeloid leukemia." @default.
- W4379340505 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.6540" @default.
- W4379340505 hasPublicationYear "2023" @default.
- W4379340505 type Work @default.
- W4379340505 citedByCount "0" @default.
- W4379340505 crossrefType "journal-article" @default.
- W4379340505 hasAuthorship W4379340505A5031081188 @default.
- W4379340505 hasAuthorship W4379340505A5053981238 @default.
- W4379340505 hasAuthorship W4379340505A5066580309 @default.
- W4379340505 hasAuthorship W4379340505A5069251789 @default.
- W4379340505 hasAuthorship W4379340505A5077058201 @default.
- W4379340505 hasAuthorship W4379340505A5079159752 @default.
- W4379340505 hasAuthorship W4379340505A5082924494 @default.
- W4379340505 hasAuthorship W4379340505A5091710463 @default.
- W4379340505 hasConcept C10205521 @default.
- W4379340505 hasConcept C119060515 @default.
- W4379340505 hasConcept C126322002 @default.
- W4379340505 hasConcept C143998085 @default.
- W4379340505 hasConcept C151956035 @default.
- W4379340505 hasConcept C176290653 @default.
- W4379340505 hasConcept C2777938653 @default.
- W4379340505 hasConcept C2778461978 @default.
- W4379340505 hasConcept C2778623314 @default.
- W4379340505 hasConcept C2778729363 @default.
- W4379340505 hasConcept C2779675984 @default.
- W4379340505 hasConcept C2781413609 @default.
- W4379340505 hasConcept C28328180 @default.
- W4379340505 hasConcept C2908647359 @default.
- W4379340505 hasConcept C512399662 @default.
- W4379340505 hasConcept C54355233 @default.
- W4379340505 hasConcept C71924100 @default.
- W4379340505 hasConcept C86803240 @default.
- W4379340505 hasConcept C99454951 @default.
- W4379340505 hasConceptScore W4379340505C10205521 @default.
- W4379340505 hasConceptScore W4379340505C119060515 @default.
- W4379340505 hasConceptScore W4379340505C126322002 @default.
- W4379340505 hasConceptScore W4379340505C143998085 @default.
- W4379340505 hasConceptScore W4379340505C151956035 @default.
- W4379340505 hasConceptScore W4379340505C176290653 @default.
- W4379340505 hasConceptScore W4379340505C2777938653 @default.
- W4379340505 hasConceptScore W4379340505C2778461978 @default.
- W4379340505 hasConceptScore W4379340505C2778623314 @default.
- W4379340505 hasConceptScore W4379340505C2778729363 @default.
- W4379340505 hasConceptScore W4379340505C2779675984 @default.
- W4379340505 hasConceptScore W4379340505C2781413609 @default.
- W4379340505 hasConceptScore W4379340505C28328180 @default.
- W4379340505 hasConceptScore W4379340505C2908647359 @default.
- W4379340505 hasConceptScore W4379340505C512399662 @default.
- W4379340505 hasConceptScore W4379340505C54355233 @default.
- W4379340505 hasConceptScore W4379340505C71924100 @default.
- W4379340505 hasConceptScore W4379340505C86803240 @default.
- W4379340505 hasConceptScore W4379340505C99454951 @default.
- W4379340505 hasFunder F4320306095 @default.
- W4379340505 hasFunder F4320306239 @default.
- W4379340505 hasFunder F4320332161 @default.
- W4379340505 hasIssue "16_suppl" @default.
- W4379340505 hasLocation W43793405051 @default.
- W4379340505 hasOpenAccess W4379340505 @default.
- W4379340505 hasPrimaryLocation W43793405051 @default.
- W4379340505 hasRelatedWork W2778071377 @default.
- W4379340505 hasRelatedWork W2778260635 @default.
- W4379340505 hasRelatedWork W2890626177 @default.
- W4379340505 hasRelatedWork W2897012503 @default.
- W4379340505 hasRelatedWork W2899717503 @default.
- W4379340505 hasRelatedWork W2914048049 @default.
- W4379340505 hasRelatedWork W2954407538 @default.
- W4379340505 hasRelatedWork W3184179839 @default.
- W4379340505 hasRelatedWork W4297982515 @default.
- W4379340505 hasRelatedWork W4301585139 @default.
- W4379340505 hasVolume "41" @default.
- W4379340505 isParatext "false" @default.
- W4379340505 isRetracted "false" @default.
- W4379340505 workType "article" @default.